| 前收市價 | 6.00 |
| 開市 | 6.00 |
| 買盤 | 4.20 |
| 賣出價 | 6.80 |
| 拍板 | 25.00 |
| 到期日 | 2025-03-21 |
| 今日波幅 | 6.00 - 6.00 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 29 |
InvestorPlaceYou’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That’s because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time. It changes the base instructions of the human body for how the body is maintained and protected. As a result, several h
ZacksBeam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.
ZacksWhy Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
